Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive-stage small-cell lung cancer:A real-world,multicenter,retrospective,controlled study in China

作     者：Hanxiao Chen Xiangjuan Ma Jie Liu Yu Yang Yong Fang Liping Wang Jian Fang Jun Zhao Minglei Zhuo Hanxiao Chen;Xiangjuan Ma;Jie Liu;Yu Yang;Yong Fang;Liping Wang;Jian Fang;Jun Zhao;Minglei Zhuo

作者机构：Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Department I of Thoracic OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Department II of Thoracic OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Department of PneumologyShandong Cancer Hospital and InstituteShandong First Medical University and Shandong Academy of Medical SciencesJinan 250117China Department of Oncologythe 2nd Affiliated Hospital of Harbin Medical UniversityHarbin 150001China Department of OncologySir Run Run Shaw Hospital Zhejiang University School of MedicineHangzhou 310020China Department of OncologyBaotou Cancer HospitalBaotou 014030China 

出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究（英文版）)

年 卷 期：2022年第34卷第4期

页      面：353-364页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by National Natural Science Foundation of China(No.82141117) the Capital Health Research and Development of Special Fund(No.2022-21023) Beijing Municipal Administration of Hospitals Incubating Program(No.PX2020045) Science Foundation of Peking University Cancer Hospital(No.2020-4) Wu Jieping Medical Foundation(No.320.6750.2021-16-19) 

主　　题：Real-world study extensive-stage SCLC atezolizumab 

摘      要：Objective:Atezolizumab along with chemotherapy has prolonged the survival of patients with extensive-stage small-cell lung cancer(ES-SCLC)worldwide,although real-world(RW)data are lacking in *** study was designed to evaluate the efficacy and clinical outcomes of atezolizumab plus etoposide/platinum(EP).Methods:Data obtained in this retrospective study were captured from six oncology units of five medical facilities from January 2019 to April *** first-line treatments,atezolizumab combined with EP *** alone,we primarily evaluated progression-free survival(PFS);other efficacy indicators,including overall survival(OS),objective response rate(ORR),and patterns of SCLC progression and adverse events(AEs)were ***:The primary analysis included data from 225 patients,of whom 133 received EP along with atezolizumab(atezolizumab group)and 92 received EP alone(EP group).The PFS duration of the atezolizumab group[7.10 months;95%confidence interval(95%CI),6.53-9.00]exceeded that of the EP group(6.50 months;95%CI,4.83-7.53).Overall,the hazard ratio(HR)was 0.69(95%CI,0.49-0.97)(P=0.029);particularly,the HR was 0.54(95%CI,0.36-0.80)among patients undergoing≥4 chemotherapy cycles and 0.33(95%CI,0.20-0.56)among individuals with atezolizumab *** ORR and disease-control rate(DCR)were similar between the two *** of incomplete OS data,the median OS was not determined for either *** marrow suppression was the most common AE detected(58.6%)in the atezolizumab ***-related AEs occurred in 19 patients in the atezolizumab group(14.3%),with only one case of grade 3 ***:This RW study in China demonstrated improved clinical outcomes of atezolizumab along with EP for ES-SCLC,particularly in the chemosensitive *** results align with the results of the IMpower133 study,although the impact of this treatment modality on OS warrants additional follow-up studies.